Form 8-K

0001171843-22-006936.txt : 20221101 0001171843-22-006936.hdr.sgml : 20221101 20221101070607 ACCESSION NUMBER: 0001171843-22-006936 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221101 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221101 DATE AS OF CHANGE: 20221101 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOCRYST PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000882796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 621413174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23186 FILM NUMBER: 221348469 BUSINESS ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-859-1302 MAIL ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 8-K 1 f8k_110122.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 1, 2022

_______________________________

BioCryst Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware	000-23186	62-1413174
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

4505 Emperor Blvd., Suite 200

Durham, North Carolina 27703

(Address of Principal Executive Offices) (Zip Code)

(919) 859-1302

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	BCRX	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 1, 2022, BioCryst Pharmaceuticals, Inc. (the “Company”) issued a press release announcing recent corporate developments and its financial results for the third quarter ended September 30, 2022, which also referenced a conference call and webcast to discuss these recent corporate developments and financial results. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

The information furnished on Exhibit 99.1 is incorporated by reference under this Item 7.01 as if fully set forth herein.

The information in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description

99.1		Press release dated November 1, 2022 entitled “BioCryst Reports Third Quarter 2022 Financial Results and Upcoming Key Milestones”
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BioCryst Pharmaceuticals, Inc.


Date: November 1, 2022	By:	/s/ Alane Barnes
		Alane Barnes
		Chief Legal Officer

EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

BioCryst Reports Third Quarter 2022 Financial Results and Upcoming Key Milestones

—$66.0 million in ORLADEYO Q3 2022 net revenue; on-track to more than double sales in 2022 vs 2021—

—Underlying patient trends remain strong with nine percent paid patient growth in Q3 2022—

—Company expands complement pipeline by advancing second oral Factor D inhibitor, BCX10013, into clinical development with goal of once-daily dosing, and adding discovery targets—

—BCX9930 patient screening underway, data expected from approximately 15 newly-enrolled patients in mid-2023—

RESEARCH TRIANGLE PARK, N.C., Nov. 01, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the third quarter ended September 30, 2022, and provided a corporate update.

“With ORLADEYO on a trajectory to more than double sales in its second year of launch after a very strong first year, we continue to demonstrate that what we are offering HAE patients is unique and fills their need for a therapy that offers both low burden of disease and low burden of treatment. We believe that our ability to successfully pursue challenging targets like plasma kallikrein is just the start, and we expect we will bring rare disease patients many more oral therapies to offer these patients the unique treatment options they are waiting for,” said Jon Stonehouse, president and chief executive officer of BioCryst.

Program Updates and Key Milestones

ORLADEYO^® (berotralstat): Oral, Once-daily Treatment for Prevention of Hereditary Angioedema (HAE) Attacks

U.S. Launch

The total number of patients on paid therapy grew by nine percent in the third quarter.
New patient starts remained strong in the third quarter, in line with the running six quarter average.
The ORLADEYO prescriber base grew by 11 percent in the third quarter.
These strong underlying growth trends were masked by accelerated direct shipments requested by patients late in the second quarter in June prior to the July 4 holiday weekend, plus a negative out of period reimbursement-related charge that was accounted for in the third quarter.

ORLADEYO: Global Updates

In the third quarter, ORLADEYO was approved in Saudi Arabia. The company expects continued approvals and launches in additional countries.

“With the strong underlying growth fundamentals we continued to see from patients and physicians in the third quarter, and the further growth dynamics we expect to see in the fourth quarter, we are on track to more than double ORLADEYO revenue in 2022 compared to 2021,” said Charlie Gayer, chief commercial officer of BioCryst.

Complement Program

BCX9930 – Oral, Twice-daily Factor D Inhibitor
- On August 4, 2022, the company announced that the U.S. Food and Drug Administration (FDA) had lifted its partial clinical hold on the BCX9930 program and that the company will resume enrollment in global clinical trials under revised protocols at a reduced dose of 400 mg twice daily of BCX9930. This includes the REDEEM-1 and REDEEM-2 pivotal trials in patients with paroxysmal nocturnal hemoglobinuria (PNH) and the RENEW proof-of-concept trial in patients with C3 glomerulopathy (C3G), immunoglobulin A nephropathy (IgAN) and primary membranous nephropathy (PMN).
- Screening has begun for new patients to participate in the trials and the company expects to have data from approximately 15 newly-enrolled patients by the middle of 2023 to inform its decision to either fully invest in the pivotal program, or to discontinue the BCX9930 program.
BCX10013 – Oral, Once-daily Factor D Inhibitor with Best-in-class Potential
- The company has begun a clinical program with BCX10013, a novel, potent and specific Factor D inhibitor, and expects to report preliminary data from healthy volunteers in the first quarter of 2023. The preclinical and early clinical profile from approximately 90 healthy volunteers to date suggests BCX10013 could have the properties of a once-daily oral therapy. A goal of the ongoing clinical program is to confirm this once-daily profile with healthy volunteer and patient data.
Additional Complement Targets
- In addition to BCX9930 and BCX10013, which target the alternative pathway of complement, BioCryst is pursuing oral medicines directed at other targets across the classical, lectin and terminal pathways of the complement system. The goal of the company’s overall complement program is to advance several oral compounds across multiple pathways in the complement system to treat many complement-mediated diseases.

BCX9250 – Oral ALK-2 Inhibitor for Fibrodysplasia ossificans progressiva (FOP)

The company believes that patients with FOP, an ultra-rare disease, are likely to benefit from other oral ALK-2 inhibitors that currently are substantially ahead of BCX9250 in development. Considering the expectation that patients will be well-served by these other products, and the approximately $100 million in additional investment that would be required to advance BCX9250 to approval, the company is stopping the BCX9250 program and redirecting this investment to the other opportunities it has to serve patients with complement-mediated diseases.

Third Quarter 2022 Financial Results

For the three months ended September 30, 2022, total revenues were $75.8 million, compared to $41.0 million in the third quarter of 2021 (+85 percent year-over-year (y-o-y)). The increase was primarily due to $66.0 million in ORLADEYO net revenue in the third quarter of 2022.

Research and development expenses for the third quarter of 2022 increased to $52.7 million from $50.0 million in the third quarter of 2021 (+6 percent y-o-y), primarily due to additional investment in the HAE program and expenses for BCX9250 prior to its discontinuation, partially offset by reduced costs related to the BCX9930 studies.

Selling, general and administrative expenses for the third quarter of 2022 increased to $36.9 million, compared to $35.0 million in the third quarter of 2021 (+6 percent y-o-y). The increase was primarily due to increased investment to support the commercial launch of ORLADEYO.

Interest expense was $24.8 million in the third quarter of 2022, compared to $14.1 million in the third quarter of 2021 (+76 percent y-o-y). The increase was due to service on the royalty financings, which were completed in November 2021. The interest payment-in-kind (PIK) option on the Athyrium term loan has been exercised and $6.5 million has been added in the third quarter of 2022 and $32.4 million since issuance, to the $200 million principal.

Net loss for the third quarter of 2022 was $42.5 million, or $0.23 per share, compared to a net loss of $58.8 million, or $0.33 per share, for the third quarter of 2021.

Cash, cash equivalents, restricted cash and investments totaled $462.6 million at September 30, 2022, compared to $203.9 million at September 30, 2021. Operating cash use for the third quarter of 2022 was $29.4 million.

Financial Outlook for 2022

Based on the strength of the ORLADEYO launch through the first three quarters of 2022, the company expects full year 2022 net ORLADEYO revenue to be $255 million.

Based on the reduced spending on the BCX9930 program in the first three quarters of the year, and lower than projected spending on the program for the remainder of the year, the company now expects operating expenses for full year 2022, not including non-cash stock compensation, to be between $365 million and $370 million.

Conference Call and Webcast

BioCryst management will host a conference call and webcast at 8:30 a.m. ET today to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 866-374-5140 for domestic callers and 404-400-0571 for international callers and using conference ID 28663801#. A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com. A replay of the call will be available on the company website.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO^® (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including oral factor D inhibitors BCX9930 and BCX10013, which are in clinical development. RAPIVAB^® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: the ongoing COVID-19 pandemic, which could create challenges in all aspects of BioCryst’s business, including without limitation delays, stoppages, difficulties and increased expenses with respect to BioCryst’s and its partners’ development, regulatory processes and supply chains, negatively impact BioCryst’s ability to access the capital or credit markets to finance its operations, or have the effect of heightening many of the risks described below or in the documents BioCryst files periodically with the Securities and Exchange Commission; BioCryst’s ability to successfully implement its commercialization plans for, and to commercialize ORLADEYO, which could take longer or be more expensive than planned; the results of BioCryst’s partnerships with third parties may not meet BioCryst’s current expectations; risks related to government actions, including that decisions and other actions, including as they relate to pricing, may not be taken when expected or at all, or that the outcomes of such decisions and other actions may not be in line with BioCryst’s current expectations; the commercial viability of ORLADEYO, including its ability to achieve market acceptance; ongoing and future preclinical and clinical development of BCX9930, BCX10013 and other product candidates may not have positive results; BioCryst may not be able to enroll the required number of subjects in planned clinical trials of product candidates; BioCryst may not advance human clinical trials with product candidates as expected; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay or withdraw market approval for products and product candidates; product candidates, if approved, may not achieve market acceptance; BioCryst’s ability to successfully commercialize its products and product candidates, manage its growth and compete effectively; risks related to the international expansion of BioCryst’s business; and actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management's expected ranges. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements.

BCRXW

Investors:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media:
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com

BIOCRYST PHARMACEUTICALS, INC.
CONSOLIDATED FINANCIAL SUMMARY
(in thousands, except per share)

Statements of Operations (Unaudited)

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2022					2021			2022					2021
Revenues:
Product sales, net	$		75,213		$		39,141		$		189,647		$		90,442
Royalty revenue			600				322				1,487				(447	)
Milestone revenue			-				-				-				15,000
Collaborative and other research and development			14				1,531				148				5,017
Total revenues			75,827				40,994				191,282				110,012

Expenses:
Cost of product sales			3,543				591				4,025				6,811
Research and development			52,740				49,971				180,090				145,279
Selling, general and administrative			36,919				34,992				109,218				83,431
Royalty			70				24				73				34
Total operating expenses			93,272				85,578				293,406				235,555

Loss from operations			(17,445	)			(44,584	)			(102,124	)			(125,543	)

Interest and other income			1,760				9				2,423				48
Interest expense			(24,775	)			(14,115	)			(72,634	)			(40,514	)
Foreign currency losses, net			(538	)			(111	)			(583	)			(274	)
Loss before income taxes			(40,998	)			(58,801	)			(172,918	)			(166,283	)
Income tax expense			1,522				-				2,657				-
Net loss	$		(42,520	)	$		(58,801	)	$		(175,575	)	$		(166,283	)

Basic and diluted net loss per common share	$		(0.23	)	$		(0.33	)	$		(0.95	)	$		(0.93	)

Weighted average shares outstanding			186,180				179,106				185,566				178,199




Balance Sheet Data (in thousands)
	September 30, 2022								December 31, 2021
	(Unaudited)								(Note 1)
Cash, cash equivalents and investments		$	461,190							$	514,430
Restricted cash			1,444								3,345
Receivables			42,610								29,413
Total assets			558,594								588,151
Secured term loan			223,867								136,082
Royalty financing obligation			489,781								449,375
Accumulated deficit			(1,383,079			)					(1,207,504			)
Stockholders’ deficit			(242,659			)					(106,986			)
Shares of common stock outstanding			186,411								184,350

Note 1: Derived from audited financial statements.

EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Nov. 01, 2022
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Nov. 01, 2022
Entity File Number	000-23186
Entity Registrant Name	BioCryst Pharmaceuticals, Inc.
Entity Central Index Key	0000882796
Entity Tax Identification Number	62-1413174
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	4505 Emperor Blvd., Suite 200
Entity Address, City or Town	Durham
Entity Address, State or Province	NC
Entity Address, Postal Zip Code	27703
City Area Code	919
Local Phone Number	859-1302
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	BCRX
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 8 f8k_110122_htm.xml IDEA: XBRL DOCUMENT 0000882796 2022-11-01 2022-11-01 iso4217:USD shares iso4217:USD shares 0000882796 false 8-K 2022-11-01 BioCryst Pharmaceuticals, Inc. DE 000-23186 62-1413174 4505 Emperor Blvd., Suite 200 Durham NC 27703 919 859-1302 false false false false Common Stock BCRX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_110122.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_110122.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "inline": { "local": [ "f8k_110122.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_110122.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_110122.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001171843-22-006936-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-22-006936-xbrl.zip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end